Form 4 for SYRE Spyre Therapeutics, Inc.

Accepted 2026-06-03 21:32:02 ET · period of report 2026-06-03 · accession 0001636282-26-000078 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DT	2026-06-03 21:32	2026-06-03	SYRE	Sloan Sheldon	Chief Medical Off	M - OptEx	$27.46	+8,333	8,333	New	+$228.8K
DT	2026-06-03 21:32	2026-06-03	SYRE	Sloan Sheldon	Chief Medical Off	S - Sale+OE	$75.00	-8,333	0	-100%	-$625.0K
DT	2026-06-03 21:32	2026-06-03	SYRE	Sloan Sheldon	Chief Medical Off	M - OptEx	$0.00	-8,333	313.3K	-3%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-06-03	M	A	8,333	$27.46	8,333	D	—	—	(F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
2	Common	Common Stock	2026-06-03	S	D	8,333	$75.00	0	D	—	—	(F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
3	Derivative	Stock Option (Right to Buy)	2026-06-03	M	D	8,333	$0.00	313,334	D	$27.46 · — to 2034-10-01	8,333 Common Stock	(F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. (F2) This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.